依达拉奉对单肺通气患者白细胞介素6和10的影响

目的观察依达拉奉对单肺通气患者围术期白细胞介素6(IL-6)和白细胞介素10(IL-10)表达的影响。方法择期拟行肺叶切除术肺癌患者24例,ASAⅠ级或Ⅱ级,年龄48～67岁,随机分为2组,对照组和依达拉奉组各12例。2组均静脉注射咪达唑仑0.03mg·kg~(-1)、芬太尼3μg·kg~(-1),吸入8%七氟醚麻醉诱导。麻醉诱导后,依达拉奉组给予依达拉奉0.5mg·kg~(1-)加入氯化钠注射液100mL,静脉滴注;对照组给予等量氯化钠注射液。2组麻醉维持用药相同,均在麻醉后切皮前(T_1)、膨肺后60min(T_2)、术后1h(T_3)测定血浆IL-6、IL-10浓度及其mRNA表达。结果与T_1比较,2组血浆IL-6、IL-10浓度和IL-6/IL-10以及IL-6mRNA、IL-10mRNA和IL-6mRNA/IL-10 mRNA于T_2、T_3均明显上升(P<0.05)。与对照组比较,依达拉奉组血浆IL-6浓度、IL-6mRNA、IL-6/IL-10和IL-6mRNA/IL-10mRNA于T_2、T_3均显著降低(P<0.05)。结论依达拉奉可有效抑制单肺通气患者IL-6的生成和释放,有助于维持IL-6/IL-10相对稳定。

Effects of edaravone on interleukin-6 and interleukin-10 in patients undergoing one-lung ventilation

AIM To investigate the effects of edaravone on interleukin-6(IL-6) and interleukin-10(IL- 10) and the expression of their mRNA in patients undergoing one-lung ventilation(OLV).METHODS Twenty-four ASAⅠorⅡpatients with lung cancer,aged 48 - 67 years,undergoing elective lung resection were randomly divided into control group and edaravone group(n = 12 each).Anesthesia was induced with midazolam 0.03 mg·kg~(-1),fentanyl 3μg·kg~(-1) and 8%sevoflurane,and maintained with same combined inhaled and intravenous anesthesia.After the induction of anesthesia,the patients in the edaravone group were received edaravone 0.5mg·kg~(-1)(diluted in sodium chloride injection 100 mL),and the patients in the control group were received with the same amount of sodium chloride injection.Blood sample were taken before skin incision(T_1),60 min after lung inflation(T_2) and 1 h after surgery(T_3) for the determination of plasma IL-6 and IL-10 concentration and the expression of their mRNA.RESULTS The levels of IL-6 and IL-10 and the expression of their mRNA were higher at T_2,T_3 than those at T_1 in both groups.IL-6 level and its mRNA,IL-6/IL-10 and IL-6 mRNA/ IL-10 mRNA were all significantly lower at T_2 and T_3 in the edaravone group than those in the control group(P<0.05).CONCLUSION Edaravone is effective in reducing plasma IL-6 and maintaining a relative stability of IL- 6/IL-10 in patients undergoing OLV.